UROV Key Statistics, Chart & Performance
The current stock price of UROV is 16.24 null. In the past month the price increased by 0.43%. In the past year, price increased by 62.89%.
UROV Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to UROV. When comparing the yearly performance of all stocks, UROV turns out to be only a medium performer in the overall market: it outperformed 43.41% of all stocks.
UROV Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to UROV. Both the profitability and financial health of UROV have multiple concerns.
UROV Financial Highlights
Over the last trailing twelve months UROV reported a non-GAAP Earnings per Share(EPS) of -5.140000000000001. The EPS decreased by -25.06% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -150.35% | ||
| ROE | N/A | ||
| Debt/Equity | -1.44 |
UROV Forecast & Estimates
UROV Ownership
About UROV
Company Profile
Urovant Sciences Ltd. is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing therapies for urologic conditions. The company's product candidate pipeline consists of vibegron, an oral, once-daily, small molecule beta-3 agonist being evaluated in an international pivotal Phase 3 clinical trial for the treatment of overactive bladder. hMaxi-K, is a novel gene therapy being developed for patients with overactive bladder who have failed oral pharmacological therapy. Urovant Sciences Ltd. is based in Floor London, United Kingdom.
Company Info
Urovant Sciences Ltd
11-12 STREET JAMES SQUARE SUITE 1 3RD FLOOR
LONDON X0 SW1Y 4LB
CEO: James Robinson
Phone: 44-0-20-7400-3347
Urovant Sciences Ltd / UROV FAQ
What does Urovant Sciences Ltd do?
Urovant Sciences Ltd. is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing therapies for urologic conditions. The company's product candidate pipeline consists of vibegron, an oral, once-daily, small molecule beta-3 agonist being evaluated in an international pivotal Phase 3 clinical trial for the treatment of overactive bladder. hMaxi-K, is a novel gene therapy being developed for patients with overactive bladder who have failed oral pharmacological therapy. Urovant Sciences Ltd. is based in Floor London, United Kingdom.
Can you provide the latest stock price for Urovant Sciences Ltd?
The current stock price of UROV is 16.24 null. The price increased by 0.06% in the last trading session.
Does UROV stock pay dividends?
UROV does not pay a dividend.
How is the ChartMill rating for Urovant Sciences Ltd?
UROV has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Can you provide the market cap for Urovant Sciences Ltd?
Urovant Sciences Ltd (UROV) has a market capitalization of 531.75M null. This makes UROV a Small Cap stock.